220 related articles for article (PubMed ID: 12163395)
1. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.
True LD; Buhler K; Quinn J; Williams E; Nelson PS; Clegg N; Macoska JA; Norwood T; Liu A; Ellis W; Lange P; Vessella R
Am J Pathol; 2002 Aug; 161(2):705-15. PubMed ID: 12163395
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.
Ellis WJ; Vessella RL; Buhler KR; Bladou F; True LD; Bigler SA; Curtis D; Lange PH
Clin Cancer Res; 1996 Jun; 2(6):1039-48. PubMed ID: 9816265
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of prostatic small-cell neuroendocrine carcinoma.
Clegg N; Ferguson C; True LD; Arnold H; Moorman A; Quinn JE; Vessella RL; Nelson PS
Prostate; 2003 Apr; 55(1):55-64. PubMed ID: 12640661
[TBL] [Abstract][Full Text] [Related]
4. LuCaP 35: a new model of prostate cancer progression to androgen independence.
Corey E; Quinn JE; Buhler KR; Nelson PS; Macoska JA; True LD; Vessella RL
Prostate; 2003 Jun; 55(4):239-46. PubMed ID: 12712403
[TBL] [Abstract][Full Text] [Related]
5. Establishing prostate cancer patient derived xenografts: lessons learned from older studies.
Russell PJ; Russell P; Rudduck C; Tse BW; Williams ED; Raghavan D
Prostate; 2015 May; 75(6):628-36. PubMed ID: 25560784
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles.
Aparicio A; Tzelepi V; Araujo JC; Guo CC; Liang S; Troncoso P; Logothetis CJ; Navone NM; Maity SN
Prostate; 2011 Jun; 71(8):846-56. PubMed ID: 21456067
[TBL] [Abstract][Full Text] [Related]
9. Small-cell neuroendocrine carcinoma of the prostate: are heterotransplants a better experimental model?
Lopez-Barcons LA
Asian J Androl; 2010 May; 12(3):308-14. PubMed ID: 20023690
[TBL] [Abstract][Full Text] [Related]
10. An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line.
Masumori N; Tsuchiya K; Tu WH; Lee C; Kasper S; Tsukamoto T; Shappell SB; Matusik RJ
J Urol; 2004 Jan; 171(1):439-42. PubMed ID: 14665950
[TBL] [Abstract][Full Text] [Related]
11. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
12. Development of seven new human prostate tumor xenograft models and their histopathological characterization.
van Weerden WM; de Ridder CM; Verdaasdonk CL; Romijn JC; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Am J Pathol; 1996 Sep; 149(3):1055-62. PubMed ID: 8780407
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells.
Gupta A; Wang Y; Browne C; Kim S; Case T; Paul M; Wills ML; Matusik RJ
Prostate; 2008 Jan; 68(1):50-60. PubMed ID: 18004726
[TBL] [Abstract][Full Text] [Related]
14. PC3 is a cell line characteristic of prostatic small cell carcinoma.
Tai S; Sun Y; Squires JM; Zhang H; Oh WK; Liang CZ; Huang J
Prostate; 2011 Nov; 71(15):1668-79. PubMed ID: 21432867
[TBL] [Abstract][Full Text] [Related]
15. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
[TBL] [Abstract][Full Text] [Related]
16. Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft model.
Uchida K; Masumori N; Takahashi A; Itoh N; Tsukamoto T
Prostate; 2005 Jan; 62(1):40-8. PubMed ID: 15389815
[TBL] [Abstract][Full Text] [Related]
17. Models of neuroendocrine prostate cancer.
Berman-Booty LD; Knudsen KE
Endocr Relat Cancer; 2015 Feb; 22(1):R33-49. PubMed ID: 25349195
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.
Corey E; Quinn JE; Emond MJ; Buhler KR; Brown LG; Vessella RL
Clin Cancer Res; 2002 Apr; 8(4):1003-7. PubMed ID: 11948106
[TBL] [Abstract][Full Text] [Related]
19. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
20. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
